Pre-made Ruplizumab benchmark antibody ( Whole mAb, anti-CD40LG therapeutic antibody, Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ruplizumab biosimilar, Whole mAb, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia.
| Products Name (INN Index) | Pre-Made Ruplizumab biosimilar, Whole mAb, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody |
|---|---|
| INN Name | Ruplizumab |
| Target | CD40LG |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 1i9r:HL:KM:XY |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2000 |
| Year Recommended | 2001 |
| Companies | Biogen |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Autoimmune disorders,Haemophilia A,Idiopathic thrombocytopenic purpura,Multiple sclerosis,Renal transplant rejection,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD40LG |
| Package |
